Key points are not available for this paper at this time.
Report preliminary efficacy and safety results for riliprubart, a novel complement C1s-inhibitor, in people with CIDP.
Querol et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: